Search
ketoprofen (Orudis Oruvail)
Tradename: Orudis, Oruvail (sustained-release).
Dose:
- 50-75 mg PO TID
- 200 mg PO QD (sustained release)
Tabs: 25, 50, 75 mg.
Sustained-release: (Oruvail) 200 mg
Adverse effects:
1) dyspepsia
2) peptic ulceration
3) gastrointestinal bleeding
4) headache
5) insomnia
6) anxiety
7) thrombocytopenia
8) anemia
9) agranulocytosis
10) rash
11) edema
12) nephrotoxicity (rare)
13) hepatotoxicity (rare)
Drug interactions:
1) salicylates
a) may divert metabolism to non-conjugated metabolites
b) displace ketoprofen from plasma protein binding sites
2) probenecid
a) may inhibit conjugation of ketoprofen
b) inhibits renal excretion of ketoprofen conjugates
3) ketoprofen may inhibit renal excretion of:
a) digoxin
b) Li+
c) methotrexate
Interactions
drug interactions
drug adverse effects of NSAIDs
monitor with non steroidal anti-inflammatory agents (NSIADs)
General
non-steroidal anti-inflammatory agent (NSAID)
Properties
INHIBITS: cyclooxygenase
MISC-INFO: elimination route LIVER
1/2life 1.1-4 HOURS
protein-binding 99%
elimination by hemodialysis -
peritoneal dialysis -
pregnancy-category B
safety in lactation -
Database Correlations
PUBCHEM correlations
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Clinical Guide to Laboratory Tests, NW Tietz (ed) 3rd ed,
WB Saunders, Philadelpha 1995